NSE · AJANTPHARM
Ajanta Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,211 Cr with net profit ₹197 Cr — a 16.3% net margin, versus 18.77% the period before.
Shareholding
As of 2026-06-30
- Promoter63.48%
- Public7.03%
- FII7.68%
- DII21.8%
65,296 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.54× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 2.76 percentage points to 63.48% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #2 of 50 by market cap · medians across 41 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,562 Cr | 84.67 | 22.07 | 25.49% | 15.55% |
| Ajanta Pharma Limited(this company) | ₹42,434 Cr | 159.09 | 9.4 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,961 Cr | 114.27 | 4.05 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,167 Cr | 326.41 | 19.57 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,863 Cr | 116.76 | 5.54 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,767 Cr | 69.25 | 5.06 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,825 Cr | 109.73 | 4.56 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,757 Cr | 79.34 | 3.89 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,071 Cr | 165.62 | 6.5 | 12.36% | 18.32% |
| Bliss GVS Pharma Ltd. | ₹4,836 Cr | 141.61 | 4.04 | 8.95% | 11.15% |
AI analysis
AI-generated · google/gemini-2.5-flashAjanta Pharma Limited is listed on the Indian markets with a market capitalization of Rs 43340 Cr. The company reported a revenue of Rs 4742.6 Cr with a revenue growth of 10.4% and a profit margin of 19.37%. Its PE ratio is 162.48 and EPS is 90.33. The book value per share stands at Rs 362.35. Return on equity is 23.33% and return on capital employed is 29.09%. The debt-to-equity ratio is 0.04.
Positives
- +The debt-to-equity ratio is low at 0.04, indicating limited reliance on debt.
- +The company demonstrated a revenue growth of 10.4%.
- +Return on Capital Employed (ROCE) is 29.09%, indicating efficient use of capital.
- +The profit margin is 19.37%.
Negatives
- −The promoter pledged 22.53% of their shareholding.
- −Promoter pledge increased from 11.16% in July 2017 to 22.53% in June 2026.
- −The trailing PE ratio of 162.48 is significantly higher compared to its EPS of Rs 90.33.
Financial performance
Ajanta Pharma Limited recorded a revenue of Rs 4742.6 Cr, indicating a revenue growth of 10.4%. The company's profit margin for the period was 19.37%. Annual net profit for Mar 2026 was Rs 1056 Cr on revenue of Rs 5624.93 Cr. Quarterly revenue for March 2026 was Rs 1421.64 Cr, with a net profit of Rs 266.7 Cr.
Profitability & Returns
The company's profit margin is 19.37%. Return on equity (ROE) is 23.33%, and return on capital employed (ROCE) is 29.09%. The earnings per share (EPS) is Rs 90.33. The latest annual EPS reported for Mar 2026 was Rs 84.51.
Balance Sheet
Ajanta Pharma Limited maintains a low debt-to-equity ratio of 0.04, suggesting a limited reliance on debt financing. The book value per share is Rs 362.35. The company’s 52-week high was Rs 3506.9 and its 52-week low was Rs 2329.9.
Ownership & Pledges
Institutional holdings include 21.80% by DIIs and 7.68% by FIIs. The public holds 7.03% of the shares. Total institutional holding stands at 29.48%. Promoter pledged shares account for 22.53% of the promoter holdings.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.